James J. Wells's blog

Can New FTC Regs Protect PR’s Stake in Digital Media?

Posted Fri, 02/05/2010 - 16:54 by James J. Wells
Posted By: James J. Wells Posted on: February 5th, 2010

My colleague Katherine Axt and I attended last week’s PRSA New York seminar, “Regulatory Scrutiny of Social Media: The Impact on PR Communicators in 2010 and Beyond“ where New York Attorney Michael Lasky walked us through the FTC’s updated guidelines concerning online Endorsements and Testimonials.

How Pharma Can Overcome FDA's Social Media Challenge

Posted Fri, 07/31/2009 - 10:08 by James J. Wells
Posted By: James J. Wells Posted on: July 31st, 2009

Speaking at last week’s Social Communications & Healthcare Conference (#BDI), Pfizer VP/Worldwide Comunications Ray Kerins said that Pfizer wants to have online conversations with its consumers. However, he thinks it is unfair to ask company employees to risk their job implementing a social media program that the FDA might later deem a violation, despite its refusal to issue guidance in this area. Nevertheless, the company just two weeks ago launched its corporate Twitter page (@Pfizer_News) and is starting to proactively communicate with its audience in real-time.

What’s the right social media channel for specific patient groups?

Posted Thu, 07/02/2009 - 09:33 by James J. Wells
Posted By: James J. Wells Posted on: July 2nd, 2009

Nothing has had a greater impact on my view of social media more than the book Groundswell, specifically its Social Technographic Profile, a research tool helping brands to identify how its customers use social media technologies. So I became intrigued when I heard that imc² adapted Forrester’s technographic profile tool for healthcare.